14 Leading Biotech Angel Investors You Should Know

For founders in the biotech and life sciences sectors, securing the right early-stage capital can define your company's trajectory.

Angel investors often play a different role than venture capital firms. They typically invest their own funds and can bring deep personal expertise to the table.

To help you find the right fit, we've put together this guide on some of the leading angel investors in the field.

Just raised or about to? Set up your financial stack with Rho in minutes. Rho provides business banking, corporate cards, accounting integrations and more—built for startup teams moving fast.

Top BioTech Angel Investors By Stage

Angel investors in biotech often concentrate on the pre-seed and seed stages, where their capital and expertise can have the greatest impact.

Knowing which investors are active at this early stage can help you find the right partners for your company's growth.

Pre-seed Angel Investors in BioTech

Pre-seed is the earliest of all startup funding types, often used to validate an idea and build a minimum viable product. For this initial capital, you might consider investors like Blake Mycoskie and Vijay Pande, who have experience with very early-stage companies.

Seed Stage Angel Investors in BioTech

Seed funding helps a startup refine its product, expand its team, and begin to establish market traction. Some angel investors active in the biotech seed stage include Peter Kellner, Christopher Dean, and Anders Hove.

Series A Angel Investors in BioTech

A Series A round is typically for companies with a proven product and consistent revenue, focusing on scaling operations and market reach. Investors like Peter Fenton and Anton Levy are known to participate in this growth stage for biotech firms.

Series B Angel Investors in BioTech

Series B funding is for more established companies looking to expand significantly, often by entering new markets or acquiring other businesses. Notable investors who participate in Series B rounds for biotech include John Doerr, Bryan Roberts, and Paul Walker.

It's also worth noting that many investors don't limit themselves to a single funding stage. Individuals like Peter Levine and Kevin Harvey, for example, have investment histories that span from seed rounds all the way to Series B.

To help you find the right partners, we've profiled some of the leading angel investors in biotech. For each investor, you'll find key details on their investment stages, sector interests, location, and what makes them a compelling choice for founders.

1. Paul Walker

Paul Walker is a General Partner at New Enterprise Associates (NEA), a prominent venture capital firm. He tends to focus on later-stage investments in biopharmaceuticals and medical devices, often supporting companies through their growth and even post-IPO stages.

His investment history shows a pattern of backing companies in Series A and B rounds, with a significant investment sweet spot around $25 million. With portfolio companies like Allakos and Geron, he shows a clear interest in biotech and pharmaceutical firms that are scaling up.

Founders with established biotech companies seeking substantial Series A or B funding may find a good partner in Paul. He is a suitable choice for teams that need significant capital and a partner with experience in guiding companies toward the public market.

• Investment stages: Series A, Series B
• Industries of focus: BioTech, Pharmaceuticals, Health IT, Health & Hospital Services
• Geographical presence: Based in Menlo Park, California
• Ideal investment range: $2.0M - $50.0M
• Notable portfolio companies: Allakos, Geron, Xenon Pharmaceuticals

You can find more information about Paul Walker on his NEA profile and Crunchbase.

2. Christopher Dean

Christopher Dean is a Managing Director at Summit Partners, where he co-heads the firm's North America Growth Equity team. His investment activity shows a particular interest in both early-seed and later-stage Series B rounds.

While his interests include biotech and digital health, his portfolio is quite varied, with investments in e-commerce and FinTech companies like Brooklinen and Celcoin. He often participates in substantial funding rounds, with a typical investment sweet spot around $20 million.

Christopher could be a great match for founders who have a strong business model and are ready for a significant capital injection to scale, even if they are at the seed stage. His broad industry experience suggests he is open to compelling opportunities across multiple technology sectors.

• Investment stages: Seed, Series B
• Industries of focus: BioTech, Health & Hospital Services, FinTech, E-commerce, Digital Health
• Geographical presence: Based in Boston, Massachusetts
• Ideal investment range: $5.0M - $50.0M
• Notable portfolio companies: ShipMonk, Brooklinen, Celcoin

You can find more information about Christopher Dean on his Summit Partners profile and LinkedIn.

3. Tyler Winklevoss

Tyler Winklevoss is a Principal at Winklevoss Capital and the Co-Founder of the crypto platform Gemini. He is widely recognized for his deep involvement in the Web3 and crypto sectors, transitioning from an early social media figure to a key investor in the blockchain ecosystem.

His investment activity shows a strong preference for early-stage companies, participating in both seed and Series A rounds. While his interests are broad, his portfolio reveals a concentration in Web3, gaming, and consumer internet, with notable investments in companies like Animoca Brands and KresusLabs.

Founders building in the Web3 or consumer-focused tech spaces may find a valuable partner in Tyler. His own experience as a founder and CEO suggests he can offer practical guidance on scaling a business in addition to capital.

• Investment stages: Seed, Series A
• Industries of focus: Web3/Crypto, BioTech, AI, Gaming/eSports, Consumer Internet
• Geographical presence: Based in New York, New York
• Ideal investment range: $100K - $5.0M
• Notable portfolio companies: Animoca Brands, KresusLabs, Octane

You can find more information about Tyler Winklevoss on the Winklevoss Capital website and his LinkedIn.

4. Peter Levine

Peter Levine is a general partner at Andreessen Horowitz (a16z), where he primarily invests in enterprise, cloud infrastructure, and AI companies. He has a background as a CEO and lecturer, bringing both operational and technical experience to his portfolio companies.

His investment activity shows a pattern of backing companies with strong technical foundations across multiple stages, from seed to Series B. With a portfolio that includes influential companies like Figma, Netlify, and Pinecone, he shows a clear preference for product-centric businesses that serve developers and enterprises.

Peter could be an excellent partner for founders building technically complex products, particularly in the infrastructure and data services sectors. His ability to invest across various funding rounds suggests he can be a long-term partner for companies as they scale.

• Investment stages: Seed, Series A, Series B
• Industries of focus: Cloud Infrastructure, Enterprise, AI, FinTech, BioTech, Data Services
• Geographical presence: Based in Menlo Park, California
• Ideal investment range: $50K - $50.0M
• Notable portfolio companies: Figma, Netlify, Pinecone, Labelbox

You can find more information about Peter Levine on his a16z profile and LinkedIn.

5. John Doerr

John Doerr is a renowned partner at the venture capital firm Kleiner Perkins. He has a long track record of supporting ambitious companies, with a particular emphasis on technology and climate-focused ventures.

His investment activity reveals a focus on companies addressing significant challenges in ClimateTech, BioTech, and cloud infrastructure. He tends to participate in Series A and B rounds, backing companies like Watershed and Visby Medical as they prepare to scale.

Founders with a clear vision for large-scale impact, especially in climate or health technology, may find a valuable partner in John. He is a suitable choice for teams seeking substantial growth capital and guidance from an experienced board member.

• Investment stages: Series A, Series B
• Industries of focus: ClimateTech/CleanTech, BioTech, Cloud Infrastructure, Education
• Geographical presence: Based in Menlo Park, California
• Ideal investment range: $100K - $25.0M
• Notable portfolio companies: Watershed, Visby Medical, Rondo Energy

You can find more information about John Doerr on his Kleiner Perkins profile and LinkedIn.

6. Kevin Harvey

Kevin Harvey is a general partner at Benchmark, a venture capital firm known for its early-stage investments. He has a history of backing companies across a wide range of funding stages, from seed rounds to Series B.

His investment activity shows a strong interest in foundational technologies like cloud infrastructure and SaaS, as well as marketplaces. With a portfolio that includes companies like Upwork and Proofpoint, he demonstrates an ability to support businesses through multiple funding rounds as they grow.

Kevin could be a great partner for founders building enterprise software or marketplace platforms. His willingness to invest across seed, Series A, and Series B rounds suggests he can be a long-term capital partner for companies on a high-growth trajectory.

• Investment stages: Seed, Series A, Series B
• Industries of focus: Cloud Infrastructure, SaaS, BioTech, Marketplaces, Social Networks
• Geographical presence: Based in Menlo Park, California
• Ideal investment range: $1.0M - $15.0M
• Notable portfolio companies: Upwork, Proofpoint, Boku

You can find more information about Kevin Harvey on the Benchmark website and his LinkedIn.

7. Anders Hove

Anders Hove is the Managing General Partner at Acorn Bioventures, with a background that includes roles at Venrock and Novartis. His extensive experience is rooted in his medical and biotechnology education, making him a well-regarded figure in life sciences investing.

His investment activity shows a clear focus on biotech, medical devices, and pharmaceuticals, with support for companies from seed to Series B stages. His portfolio includes companies like Intuity Medical and Anacor Pharmaceutical, reflecting his ability to back businesses through their growth cycles.

Founders with a strong scientific foundation in the life sciences may find a great partner in Anders. He is particularly well-suited for teams that need a capital partner with deep operational and financial experience in the pharmaceutical and biotech industries.

• Investment stages: Seed, Series A, Series B
• Industries of focus: BioTech, Medical Devices, Pharmaceuticals
• Geographical presence: Based in New York, New York
• Ideal investment range: $100K - $5.0M
• Notable portfolio companies: Intuity Medical, Anacor Pharmaceutical, Edge Therapeutics

You can find more information about Anders Hove on his firm's website and his LinkedIn.

8. Blake Mycoskie

Blake Mycoskie is the founder of TOMS and an active angel investor known for backing mission-driven companies. He invests his personal funds and brings deep experience in building consumer brands from the ground up.

His investment activity is concentrated at the seed stage, with a clear interest in health, wellness, and consumer-focused businesses. With his background as a founder, he can offer practical guidance on brand building, as shown by his investments in companies like Liquid Death and Athletic Brewing.

Blake could be a great partner for founders at the earliest stages, especially those creating consumer brands with a strong story or social mission. Teams that value operational experience and a purpose-driven approach may find him to be a good fit.

• Investment stages: Seed
• Industries of focus: Health & Hospital Services, Fashion, Digital Health, BioTech, Health IT
• Geographical presence: Based in Los Angeles, California
• Ideal investment range: $5K - $50K
• Notable portfolio companies: Liquid Death, Athletic Brewing, Back to the Roots

You can find more information about Blake Mycoskie on his website and LinkedIn.

9. Peter Kellner

Peter Kellner is the Founder and Managing Partner of Richmond Global Ventures. He is an active seed-stage investor with a notably diverse portfolio that spans multiple industries.

He concentrates on the seed stage, and his interests are broad, including Impact, PropTech, and BioTech. His portfolio includes international companies like Kueski and Guiabolso, suggesting an interest in global markets.

Founders at the seed stage with a strong business model in sectors like consumer health, climate tech, or real estate may find him to be a good fit. His wide-ranging interests indicate he is open to compelling ideas across many fields.

• Investment stages: Seed
• Industries of focus: Impact, Real Estate/PropTech, Consumer Health, BioTech, ClimateTech/CleanTech
• Geographical presence: Based in Boston, Massachusetts
• Ideal investment range: $200K - $2.0M
• Notable portfolio companies: Kueski, Guiabolso, Siftery

You can find more information about Peter Kellner on his firm's website and his LinkedIn.

10. Thomas Jennings

Thomas Jennings is a Managing Director at Summit Partners, where he has been a part of the team since 1997. He generally concentrates on later-stage investments, particularly within the healthcare and software sectors.

His investment activity shows a clear focus on Series B rounds, with a typical investment sweet spot around $20 million. His participation in a $20 million funding round for Accedian highlights his interest in providing significant growth capital to established companies.

Founders with businesses in health tech or SMB software that are ready for a substantial Series B round may find a good partner in Thomas. He is a suitable choice for teams looking for a capital partner to help scale their operations significantly.

• Investment stages: Series B
• Industries of focus: Health & Hospital Services, Digital Health, BioTech, Health IT, SMB Software
• Geographical presence: Based in Boston, Massachusetts
• Ideal investment range: $5.0M - $50.0M
• Notable portfolio companies: Accedian, PeerApp

You can find more information about Thomas Jennings on his Summit Partners profile and LinkedIn.

11. Anton Levy

Anton Levy is a Co-President and the Global Head of Technology Investing at General Atlantic. He is known for backing high-growth technology companies across the globe.

His investment activity shows a focus on both early and growth-stage companies, with a tendency to participate in substantial funding rounds. His portfolio includes well-known companies like Squarespace and HiBob, indicating an interest in businesses with proven models ready to scale.

Anton may be a good partner for founders of technology companies that have already found product-market fit and are seeking significant capital for expansion. His experience with large-scale investments suggests he can support companies through major growth phases.

• Investment stages: Seed, Series A
• Industries of focus: FinTech, Enterprise, Consumer Internet, Digital Health, BioTech
• Geographical presence: Based in New York, New York
• Ideal investment range: $20.0M - $100.0M
• Notable portfolio companies: Squarespace, HiBob, Bolt, Chronosphere

You can find more information about Anton Levy on the General Atlantic website and his LinkedIn.

12. Peter Fenton

Peter Fenton is a General Partner at Benchmark, a well-known venture capital firm. He has a long history of backing foundational technology companies, drawing from his previous experience as a managing partner at Accel.

His investment activity shows a pattern of supporting companies across multiple funding stages, from seed to Series B. With a portfolio that includes Docker, Cockroach Labs, and Timescale, he has a clear interest in product-centric businesses in cloud infrastructure and enterprise software.

Founders building technically complex products may find a strong partner in Peter. He is a good fit for teams that need a long-term investor who can provide capital and guidance through various growth phases.

• Investment stages: Seed, Series A, Series B
• Industries of focus: Cloud Infrastructure, Enterprise, BioTech, Marketplaces, Consumer Internet
• Geographical presence: Based in Palo Alto, California
• Ideal investment range: $2.0M - $20.0M
• Notable portfolio companies: Docker, Cockroach Labs, Timescale, Digits

You can find more information about Peter Fenton on the Benchmark website and his LinkedIn.

13. Bryan Roberts

Bryan Roberts is a Partner at Venrock, where he brings a deep scientific background to his investment decisions. With a Ph.D. in Chemistry and Chemical Biology from Harvard, he is well-known for his work with healthcare and biotech companies.

His investment activity shows a pattern of backing companies in their Series A and B rounds, with a typical investment sweet spot around $10 million. His portfolio, which includes companies like Element Biosciences and Suki, reflects a strong interest in biotech and health IT businesses that are ready to scale.

Bryan could be an excellent partner for founders in the life sciences or health tech sectors who have a strong scientific foundation. He is a good fit for teams seeking a substantial capital partner with the technical expertise to understand their product and market.

• Investment stages: Series A, Series B
• Industries of focus: Health & Hospital Services, BioTech, Health IT, Medical Devices
• Geographical presence: Based in San Francisco, California
• Ideal investment range: $2.0M - $40.0M
• Notable portfolio companies: Element Biosciences, Suki, Stride Health

You can find more information about Bryan Roberts on his Venrock profile and LinkedIn.

14. Vijay Pande

Vijay Pande is a General Partner at Andreessen Horowitz (a16z), where he leads investments in companies at the intersection of biology and computer science. He is well-regarded for his deep academic and scientific background, having been a professor at Stanford and the founding director of the Folding@home project.

His investment activity shows a commitment to companies from the seed stage through Series B, with a focus on BioTech, pharmaceuticals, and digital health. With a portfolio that includes companies like BioAge Labs and Asimov, he has a clear interest in businesses using computational approaches to solve complex biological problems.

Vijay could be an excellent partner for founders with deep technical or scientific expertise who are building platforms in the life sciences. He is a good fit for teams that need an investor who understands complex science and can provide support from the earliest stages of company building.

• Investment stages: Seed, Series A, Series B
• Industries of focus: BioTech, Pharmaceuticals, Digital Health, Health IT
• Geographical presence: Based in San Francisco, California
• Ideal investment range: $100K - $10.0M
• Notable portfolio companies: BioAge Labs, Asimov, Genesis Therapeutics, Devoted Health

You can find more information about Vijay Pande on his a16z profile and LinkedIn.

What Startup Founders Should Look for in a BioTech Investor

When seeking a biotech angel investor, look beyond just the capital. The right partner brings relevant industry experience, a valuable network, and an investment philosophy that aligns with your company's long-term vision.

As our list shows, many prominent investors are based in key biotech hubs like the Bay Area and Boston. While some have deep scientific backgrounds, others bring perspectives from different sectors, which can be equally beneficial for a growing company.

Evaluate an investor's typical check size, preferred stage, and portfolio to gauge fit. Many investors support companies across multiple funding rounds, signaling their potential as a long-term partner as you scale.

The best investor is one who understands your specific challenges and provides both the financial backing and strategic guidance needed to succeed.

Raise Confidently with Rho

Fundraising requires your full attention, and a focused list of relevant investors saves you critical time and energy. Using this guide to identify the right partners is a productive first step in your outreach.

Once you secure funding, Rho can help you set up your financial stack in minutes. We provide business banking, corporate cards, and bill pay solutions built to get your startup running efficiently.

This setup helps direct your newly acquired angel capital toward growth and key operations, rather than losing it to time-consuming financial admin.

FAQs about BioTech Angel Investors

Are there biotech angel investors in emerging hubs like New York?

Yes, while Boston and the Bay Area are major centers, other cities have strong biotech ecosystems. You can find active angel investors in New York and other growing hubs who are keen on life sciences.

How do angel investors view biotech startups using AI?

Investors are increasingly interested in companies applying AI to drug discovery, diagnostics, and clinical trials. Demonstrating how your AI provides a clear, defensible advantage can make your pitch more compelling to investors focused on AI.

What is the difference between an angel investor and an angel group?

An individual angel invests their own money, while an angel group is a formal organization where members pool capital and expertise to invest in startups together. Groups often streamline the due diligence process for both parties.

Do biotech angels invest before a product is fully developed?

Many do, especially at the earliest stages. Pre-seed and seed investors in biotech often back strong scientific concepts and founding teams, providing the capital needed to reach key research and development milestones before a final product exists.

How should I manage my capital after securing angel investment?

After fundraising, it's crucial to have a robust financial system. Our platform helps you manage your new capital with business banking, corporate cards, and automated payables, so you can focus on growth. Get started with Rho.